Hepatitis C virus recurrence after liver transplantation: Biomarkers of disease and fibrosis progression

Expert Review of Gastroenterology and Hepatology

Volumn 4, Issue 4, 2010, Pages 445-458

  Maluf, Daniel G ^a   Archer, Kellie J ^a   Villamil, Federico ^b   Stravitz, Richard Todd ^a   Mas, Valeria ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

Author keywords

biomarkers; cirrhosis; hepatitis C virus; liver fibrosis; liver transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HYALURONIC ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; VASCULAR CELL ADHESION MOLECULE 1;

DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; END STAGE LIVER DISEASE; FIBROGENESIS; GENE EXPRESSION PROFILING; GRAFT SURVIVAL; HEPATITIS C; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION RISK; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER INJURY; LIVER TRANSPLANTATION; NONHUMAN; POSTOPERATIVE INFECTION; RECURRENT INFECTION; REINFECTION; REVIEW; TREATMENT INDICATION; UNITED STATES; VIRUS PATHOGENESIS;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; GRAFT SURVIVAL; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; RECURRENCE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 77955235004     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.10.39     Document Type: Review

References (97)

1. Alter MJ. Epidemiology of hepatitis C. Hepatology 26, S62-S65 (1997).
2. Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver diseases in the United States: summary of a workshop. Hepatology 36, 227-242 (2002).
3. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 9, 331-338 (2003).
4. Garcia-Retortillo M, Forns X, Feliu A et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 35, 680-687 (2002).
5. Laskus T, Radkowski M, Wilkinson J, Vargas H, Rakela J. The origin of hepatitis C virus reinfecting transplanted livers: serum-derived versus peripheral blood mononuclear cell-derived virus. J. Infect. Dis. 185, 417-421 (2002).
6. Ducoulombier D, Roque-Afonso AM, Di Liberto G et al. Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology 39, 817-825 (2004).
7. Blasco A, Forns X, Carrion JA et al. Hepatic venous pressure gradient identifes patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 43, 492-499 (2006).
8. Neumann UP, Berg T, Bahra M et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J. Hepatol. 41, 830-836 (2004).
9. Wiesner RH, Sorrell M, Villamil F. Report of the frst International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl. 9, S1-S9 (2003).
10. Futagawa Y, Terasaki PI, Waki K, Cai J, Gjertson DW No improvement in long-term liver transplant graft survival in the last decade: an analysis of the UNOS data. Am. J. Transplant. 6, 1398-1406 (2006).
11. Garcia-Retortillo M, Forns X, Feliu A et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 35, 680-687 (2002).
12. Fukumoto T, Berg T, Ku Y et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology 24, 1351-1354 (1996).
13. Moll C, Kähler C, Edis C et al. Early-level hepatitis C viremia after orthotopic liver transplantation is of prognostic signifcance. Transplant. Proc. 30, 698-700 (1998).
14. Yilmaz N, Shiffman ML, Stravitz RT et al A prospective evaluation of fbrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl. 13, 975-983 (2007).
15. Prieto M, Berenguer M, Rayón JM et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 29, 250-256 (1999).
16. Alsatie M, Chalasani N, Kwo PY Management of hepatitis C infection after liver transplantation. Drugs 67, 871-885 (2007).
17. Garcia-Retortillo M, Forns X, Feliu A et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 35, 680-687 (2002).
18. Fukumoto T, Berg T, Ku Y et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology 24, 1351-1354 (1996).
19. Moll C, Kähler C, Edis C et al. Early-level hepatitis C viremia after orthotopic liver transplantation is of prognostic signifcance. Transplant. Proc. 30, 698-700 (1998).
20. Gane EJ, Portmann BC, Naoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N. Engl. J. Med. 334, 815-820 (1996).
21. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122, 889-896 (2002).
22. Pelletier SJ, Iezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL. Prediction of liver allograft fbrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinfammatory activity. Liver Transpl. 6, 44-53 (2000).
23. Prieto M, Berenguer M, Rayón JM et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 29, 250-256 (1999).
24. Slapak GI, Saxena R, Portmann B et al. Graft and systemic disease in long-term survivors of liver transplantation. Hepatology 2, 195-202 (1997).
25. Berenguer M, Prieto M, San Juan F et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 36, 202-210 (2002).
26. Berenguer M, Rayón JM, Prieto M et al. Are posttransplantation protocol liver biopsies useful in the long term? Liver Transpl. 7, 790-796 (2001).
27. Féray C, Caccamo L, Alexander GJ et al. European collaborative study on factors infuencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 117, 619-625 (1999).
28. Sánchez-Fueyo A, Restrepo JC, Quintó L et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 73, 56-63 (2002).
29. Berenguer M, Ferrell L, Watson J et al. HCV-related fbrosis progression following liver transplantation: increase in recent years. J. Hepatol. 32, 673-684 (2000).
30. Domínguez-Gil B, Morales JM. Transplantation in the patient with hepatitis C. Transpl. Int. 22(12), 1117-1131 (2009).
31. Roche B, Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. J. Viral. Hepat. 14(Suppl. 1), 89-96 (2007).
32. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J. Hepatol. 35, 666-678 (2001).
33. Pruthi J, Medkiff KA, Esrason KT et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl. 7, 811-815 (2001).
34. Bruno R, Sacchi P, Puoti M et al. Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. J. Acquir. Immune Defc. Syndr. 46(3), 297-303 (2007).
35. Roche B, Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. J. Viral. Hepat. 14(Suppl. 1), 89-96 (2007).
36. Zekry A, Bishop GA, Bowen DG et al. Intrahepatic cytokine profles associated with posttransplantation hepatitis C virus-related liver injury. Liver Transpl. 8, 292-301 (2002).
37. Ryder SD, Irving WL, Jones DA et al. Trent Hepatitis C Study Group. Progression of hepatic fbrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 53, 451-455 (2004).
38. Shiffman ML. Natural history and risk factors for progression of hepatitis C virus disease and development of hepatocellular cancer before transplantation. Liver Transpl. 9, S14-S19 (2003).
39. Wright M, Goldin R, Fabre A et al. HENCORE collaboration. Measurement and determinants of the natural history of liver fbrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 52, 574-579 (2003).
40. Firpi RJ, Abdelmalek MF, Soldevila-Pico C et al. One-year protocol liver biopsy can stratify fbrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl. 10,1240-1247 (2004).
41. Gallegos-Orozco JF, Yosephy A, Noble B et al. Natural history of post-liver transplantation hepatitis C: a review of factors that may infuence its course. Liver Transpl. 15(12), 1872-1881 (2009).
42. Abdelmalek MF, Firpi RJ, Soldevila-Pico C et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl. 10, 199-207 (2004).
43. Chalasani N, Manzarbeitia C, Ferenci P et al.; Regasys Transplant Study Group. Peginterferon a-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 41, 289-298 (2005).
44. McCaughan GW, Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl. 8(10, Suppl. 1), S7-S13 (2002).
45. Schluger LK, Sheiner PA, Thung SN et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 23, 971-976 (1996).
46. Dixon LR, Crawford JM. Early histologic changes in fbrosing cholestatic hepatitis C. Liver Transpl. 13(2), 219-226 (2007).
47. McCaughan GW, Zekry A. Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection. Transpl. Infect. Dis. 2, 166-185 (2000).
48. Arenas JI, Vargas HE, Rakela J. The use of hepatitis C-infected grafts in liver transplantation. Liver Transpl. 9, S48-S51 (2003).
49. Ramírez S, Pérez-Del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl. 14(Suppl. 2), S27-S35 (2008).
50. Weston SJ, Leistikow RL, Reddy KR et al Reconstitution of hepatitis C virus-specifc T-cell mediated immunity after liver transplantation. Hepatology 41 (1), 72-81 (2005).
51. + T cells recognize multiple HCV epitopes and produce interferon g. Hepatology 32, 597-603 (2000).
52. Russo M, Firpi R, Nelson D, Schoonhoven R, Shretha R, Fried M. Early hepatic stellate cell activation is associated with advance fbrosis after liver transplantation in recipients with hepatitis C. Liver Transpl. 11, 1235-1241 (2005).
53. Berenguer M, Aguilera V, Prieto M et al. Delayed onset of sever hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl. 9, 1152-1158 (2003).
54. Thuluvath PJ, Guidinger MK, Fung JJ et al. Liver transplantation in the United States, 1999-2008. Am. J. Transplant. 10, 1003-1019 (2010).
55. Mutimer DJ, Gunson B, Chen J et al. Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. Transplantation 81, 7-14 (2006).
56. Afdhal NH. Diagnosing fbrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology 37, 972-974 (2003).
57. Dienstag J. The role of liver biopsy in chronic hepatitis C. Hepatology 36, S152-S160 (2002).
58. Samuel D, Forns X, Berenguer M et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J. Hepatol. 45, 127-143 (2006).
59. Benlloch S, Heredia L, Barquero C et al. Prospective validation of a noninvasive index for predicting liver fbrosis in hepatitis C virus-infected liver transplant recipients. Liver Transpl. 15(12), 1798-1807 (2009).
60. Pungpapong S, Nunes DP, Krishna M et al. Serum fbrosis markers can predict rapid fbrosis progression after liver transplantation for hepatitis C. Liver Transpl. 14(9), 1294-1302 (2008).
61. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fbrosis: a systematic review of diagnostic test accuracy. Am. J. Gastroenterol. 102, 2589-2600 (2007).
62. Bosch J, Abraldes JG, Berzigotti A, García-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat. Rev. Gastroenterol. Hepatol. 6(10), 573-582 (2009)
63. Russo MW, Firpi RJ, Nelson DR, Schoonhoven R, Shrestha R, Fried MW. Early hepatic stellate cell activation is associated with advanced fbrosis after liver transplantation in recipients with hepatitis C. Liver Transpl. 11(10), 1235-1241 (2005).
64. Sawyers CL. The cancer biomarker problem. Nature 452(7187), 548-552 (2008).
65. van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452(7187), 564-570(2008).
66. Neusser MA, Lindenmeyer MT, Kretzler M, Cohen CD. Genomic analysis in nephrology-towards systems biology and systematic medicine? Nephrol. Ther. 4(5), 306-311 (2008).
67. Kurian S, Grigoryev Y, Head S, Campbell D, Mondala T, Salomon DR. Applying genomics to organ transplantation medicine in both discovery and validation of biomarkers. Int. Immunopharmacol. 7(14), 1948-1960 (2007).
68. Knechtle SJ, Kwun J. Unique aspects of rejection and tolerance in liver transplantation. Semin. Liver Dis. 29(1), 91-101 (2009).
69. Burton JR Jr, Rosen HR. Acute rejection in HCV-infected liver transplant recipients: the great conundrum. Liver Transpl. 12(11 Suppl. 2), S38-S47 (2006).
70. Manousou P, Samonakis D, Cholongitas E et al. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl. 15(12), 1783-1791 (2009).
71. Gelb B, Feng S. Management of the liver transplant patient. Expert Rev. Gastroenterol. Hepatol. 3(6), 631-647 (2009).
72. Regev A, Molina E, Moura R et al. Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation. Liver Transpl. 10(10), 1233-1239 (2004).
73. Schmeding M, Dankof A, Krenn V et al. C4d in acute rejection after liver transplantation-a valuable tool in differential diagnosis to hepatitis C recurrence. Am. J. Transplant. 6(3), 523-530 (2006).
74. Jain A, Ryan C, Mohanka R et al. Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in post-liver transplant biopsies. Clin. Transplant. 20(5), 624-633 (2006).
75. Cabrera R, Ararat M, Soldevila-Pico C et al. Using an immune functional assay to differentiate acute cellular rejection from recurrent hepatitis C in liver transplant patients. Liver Transpl. 15(2), 216-222 (2009).
76. Rubinas T, Dellon E, Henel G. Use of an immune functional assay to differentiate recurrent hepatitis C from acute cellular rejection in liver transplant patients. Liver Transpl. 15(9), 1157 (2009).
77. + T-cell function in predicting allograft rejection and recurrent hepatitis C after liver transplantation. Clin. Transplant. DOI: 10.1111/j.1399-0012. 2009.01169.x (2009) (Epub ahead of print).
78. Khatri P, Sarwal MM. Using gene arrays in diagnosis of rejection. Curr. Opin. Organ Transplant. 14(1), 34-39 (2009).
79. Ying L, Sarwal M. In praise of arrays. Pediatr. Nephrol. 24(9), 1643-1659; quiz 1655, 1659 (2009).
80. Weintraub LA, Sarwal MM. Microarrays: a monitoring tool for transplant patients? Transpl. Int. 19(10), 775-788 (2006).
81. Sreekumar R, Rasmussen DL, Wiesner RH, Charlton MR. Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation. Liver Transpl. 8, 814-821 (2002).
82. Macquillan GC, de Boer WB, Allan JE, Platten MA, Reed WD, Jeffrey GP. Hepatocellular MxA protein expression supports the differentiation of recurrent hepatitis C disease from acute cellular rejection after liver transplantation. Clin. Transplant. 24(2), 252-258 (2010).
83. Mas V, Maluf D, Archer K, Stravitz RT, Posner M, Fisher RA. HCV recurrence post-transplantation: molecular pathways affected in the allograft. Presented at: 15th Annual International Congress. NY, USA, 8-11 July 2009.
84. Asaoka T, Kato T, Marubashi S et al. Differential transcriptome patterns for acute cellular rejection in recipients with recurrent hepatitis C after liver transplantation. Liver Transpl. 15(12), 1738-1749 (2009).
85. Micheloud D, Salcedo M, Bañares R et al. Serum levels of fbrosis biomarkers measured early after liver transplantation are associated with severe hepatitis C virus recurrence. Transpl. Infect. Dis. 11(2), 183-188 (2009).
86. Carrión JA, Fernández-Varo G, Bruguera M et al. Serum fbrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology 138(1), 147-158.e1 (2010).
87. Smith MW, Walters KA, Korth MJ et al. Gene expression patterns that correlate with hepatitis C and early progression to fbrosis in liver transplant recipients. Gastroenterology 130(1), 179-187 (2006).
88. Carpentier A, Conti F, Stenard F et al. Increased expression of regulatory Tr1 cells in recurrent hepatitis C after liver transplantation. Am. J. Transplant. 9(9), 2102-2112 (2009).
89. Mas V, Maluf D, Potter A, Archer K, Suh JL, Descalzi V, Villamil F. Genomics analysis of formalin-fxed paraffn embedded liver biopsies to predict severity of HCV recurrence. Presented at: 15th Annual International Congress. NY, USA, 8-11 July 2009.
90. Burra P. Hepatitis C. Semin. Liver Dis. 29(1), 53-65 (2009).
91. D'Errico-Grigioni A, Fiorentino M, Vasuri F et al. Tissue hepatitis C virus RNA quantifcation and protein expression help identify early hepatitis C virus recurrence after liver transplantation. Liver Transpl. 14(3), 313-320 (2008).
92. Grassi A, Quarneti C, Ravaioli M et al. Detection of HCV antigens in liver graft: relevance to the management of recurrent post-liver transplant hepatitis C. Liver Transpl. 12(11), 1673-1681 (2006).
93. Unitt E, Gelson W, Davies SE et al. Minichromosome maintenance protein-2-positive portal tract lymphocytes distinguish acute cellular rejection from hepatitis C virus recurrence after liver transplantation. Liver Transpl. 15(3), 306-312 (2009).
94. Corradi F, Piscaglia F, Flori S et al. Assessment of liver fbrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography. Dig. Liver Dis. 41(3), 217-225 (2009).
95. Harada N, Soejima Y, Taketomi A et al. Assessment of graft fbrosis by transient elastography in patients with recurrent hepatitis C after living donor liver transplantation. Transplantation 85(1), 69-74 (2008).
96. Carrión JA, Fernández-Varo G, Bruguera M et al. Serum fbrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology 138(1), 147-158 (2010).
97. Toniutto P, Fabris C, Bitetto D et al. Role of AST to platelet ratio index in the detection of liver fbrosis in patients with recurrent hepatitis C after liver transplantation. J. Gastroenterol. Hepatol. 22(11), 1904-1908 (2007).